The Europe Transcatheter Aortic Valve Replacement Market would witness market growth of 6.8% CAGR during the forecast period (2022-2028).
Several research groups are participating in a clinical research program that keeps running and enables patients’ access to cutting-edge technologies. Some examples of more recent experimental technology are TAVR valves with a smaller diameter, valves with improved sealing, and valves that may be adjusted for more precise placement.
The market opportunities being established by market participants due to the quick pace of clinical research in TAVR Innovations will benefit many heart patients who will profit from TAVR as a procedure for heart valve dysfunction. AVR is performed through extremely small gaps without jarring the chest bones.
As a result, the heart's aortic valve becomes thicker and calcified, preventing it from opening fully and reducing blood flow from the heart to the body's other organs. Heart failure and sudden heart fatalities may result from this. Patients experiencing symptoms and evidence of aortic stenosis are advised to undergo the implant. Patient's quality of life is enhanced with TAVR even if they would otherwise have few remaining therapy alternatives.
Over 1.8 million people in the European Union (EU) and 3.9 million people in Europe lose their lives to cardiovascular disease every year. Furthermore, 37% of all EU fatalities are attributable to CVD. The mortality rates from ischemic heart disease (IHD) and stroke are greater in Central and Eastern Europe compared to Northern, Southern, and Western Europe. Estimates place the number of people with CVD in Europe at 85 million, with about 49 million in the EU. This provides the participants in the transcatheter aortic valve replacement market in the Europe region with excellent growth potential.
The Germany market dominated the Europe Transcatheter Aortic Valve Replacement Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $519.1 million by 2028. The UK market is anticipated to grow at a CAGR of 5.9% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 7.6% during (2022 - 2028).
Based on Material, the market is segmented into Nitinol, Stainless Steel, Cobalt-Chromium and Others. Based on Implantation Procedure, the market is segmented into Transfemoral, Transapical and Transaortic. Based on Mechanism, the market is segmented into Balloon-expanding Valve and Self-expanding Valve. Based on End-use, the market is segmented into Hospitals, Ambulatory Surgical Centers and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Transcatheter Aortic Valve Replacement Market will Hit $8 Billion by 2028, at a CAGR of 7.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, Edwards Lifesciences Corporation, MicroPort Scientific Corporation, LivaNova PLC, TTK Healthcare Limited, Meril Life Science Private Limited, JenaValve Technology, Inc., and Bracco S.p.A.
By Material
By Implantation Procedure
By Mechanism
By End-use
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
